Try our beta test site
63 studies found for:    TMC435 phase 3
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alfa-2a (pegIFN alfa-2a);   Drug: Ribavirin (RBV)
2 Completed
Has Results
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: TMC435;   Drug: Peginterferon alfa-2a (PegIFNα-2a );   Drug: Ribavirin (RBV)
3 Completed
Has Results
3-year Follow-up Study in Patients Previously Treated With a TMC435 for the Treatment of Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C
Intervention: Drug: No treatment
4 Completed A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
Conditions: Hepatitis C, Chronic;   Infection
Interventions: Drug: TMC435;   Drug: Pegylated interferon alfa-2a (PegIFNα-2a);   Drug: Ribavirin (RBV)
5 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
Condition: Hepatitis C
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alpha-2a (PegIFN alpha-2a);   Drug: Ribavirin (RBV)
6 Completed
Has Results
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
Condition: Hepatitis C
Interventions: Drug: TMC435;   Drug: Placebo;   Drug: Peginterferon alpha-2a (PegIFN alpha-2a);   Drug: Ribavirin (RBV)
7 Completed
Has Results
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
Conditions: Chronic Hepatitis C;   Genotype 4 Chronic Hepatitis C
Interventions: Drug: Simeprevir;   Drug: Sofosbuvir
8 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
Condition: Hepatitis C
Interventions: Drug: Placebo;   Drug: TMC435;   Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b);   Drug: Ribavirin (RBV)
9 Completed
Has Results
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: Simeprevir;   Drug: Sofosbuvir
10 Completed
Has Results
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: Simeprevir;   Drug: Sofosbuvir
11 Completed
Has Results
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
Condition: Hepatitis C
Interventions: Drug: TMC435;   Drug: TVR
12 Completed A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
Condition: Hepatitis C
Intervention: Drug: TMC435
13 Completed
Has Results
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: TMC435;   Drug: Peginterferon alfa-2b (pegIFN alfa-2b);   Drug: Ribavirin (RBV)
14 Completed
Has Results
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
Condition: Hepatitis C Virus Genotype-1
Interventions: Drug: TMC435;   Drug: Pegylated interferon alpha-2a;   Drug: Ribavirin
15 Completed A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients
Condition: Hepatitis C
Intervention: Drug: TMC435
16 Completed
Has Results
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: TMC435;   Drug: Pegylated interferon (pegIFN alpha-2a);   Drug: Ribavirin (RBV)
17 Completed
Has Results
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: TMC435;   Drug: Peginterferon-alpha (PegIFNα-2a);   Drug: Ribavirin (RBV);   Drug: Placebo
18 Completed TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration
Condition: Hepatitis C Virus
Interventions: Drug: TMC435 (G006);   Drug: TMC435 (F021);   Drug: TMC435 (G007)
19 Completed A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.
Condition: Healthy Volunteers
Interventions: Drug: TMC435 150 mg capsule;   Drug: TMC435 150 mg oral suspension (20 mg/mL);   Drug: TMC435 150 mg oral solution (10 mg/mL);   Drug: TMC435 150 mg capsule concept K;   Drug: TMC435 150 mg capsule concept L
20 Completed TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435
Condition: Hepatitis C Virus
Intervention: Drug: TMC435

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.